Studies on muscarinic binding sites in human brain identified with [3H]pirenzepine - PubMed (original) (raw)

Studies on muscarinic binding sites in human brain identified with [3H]pirenzepine

S C Lin et al. J Neurochem. 1986 Jan.

Abstract

Pirenzepine, a potent antimuscarinic agent with apparent selectivity for a subtype (M1) of muscarinic receptors, was used in tritiated form to characterize its binding to human brain tissue. Specific [3H]pirenzepine binding showed rapid association and dissociation. From kinetic and competitive binding experiments, its KD was 5.5 nM and 9 nM, respectively. Regional distribution of [3H]pirenzepine binding determined in parallel with [3H]quinuclidinyl benzilate binding, a nonselective muscarinic antagonist, indicated a significant correlation for the maximum number of binding sites for the two radioligands in 13 brain regions, with the highest amount of binding for each in the putamen and the least in the cerebellum. Binding for [3H]pirenzepine averaged 57% of that for [3H]quinuclidinyl benzilate, with a range of 20% (cerebellum) to 77% (frontal cortex). Most antidepressants and neuroleptics tested had affinities for [3H]pirenzepine binding sites that were not significantly different from their previously reported values obtained with the use of [3H]quinuclidinyl benzilate.

PubMed Disclaimer

Similar articles

• Multiple binding affinities of N-methylscopolamine to brain muscarinic acetylcholine receptors: differentiation from M1 and M2 receptor subtypes.
  el-Fakahany EE, Ramkumar V, Lai WS. el-Fakahany EE, et al. J Pharmacol Exp Ther. 1986 Aug;238(2):554-63. J Pharmacol Exp Ther. 1986. PMID: 3755473
• Regional distribution of M1, M2 and non-M1, non-M2 subtypes of muscarinic binding sites in rat brain.
  Ehlert FJ, Tran LP. Ehlert FJ, et al. J Pharmacol Exp Ther. 1990 Dec;255(3):1148-57. J Pharmacol Exp Ther. 1990. PMID: 2262898

Cited by

• An acute effect of triazolam on muscarinic cholinergic receptor binding in the human brain measured by positron emission tomography.
  Suhara T, Inoue O, Kobayashi K, Satoh T, Tateno Y. Suhara T, et al. Psychopharmacology (Berl). 1994 Jan;113(3-4):311-7. doi: 10.1007/BF02245202. Psychopharmacology (Berl). 1994. PMID: 7862838 Clinical Trial.
• Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study.
  Asahina M, Suhara T, Shinotoh H, Inoue O, Suzuki K, Hattori T. Asahina M, et al. J Neurol Neurosurg Psychiatry. 1998 Aug;65(2):155-63. doi: 10.1136/jnnp.65.2.155. J Neurol Neurosurg Psychiatry. 1998. PMID: 9703164 Free PMC article.
• Mapping of human and macaque sensorimotor areas by integrating architectonic, transmitter receptor, MRI and PET data.
  Zilles K, Schlaug G, Matelli M, Luppino G, Schleicher A, Qü M, Dabringhaus A, Seitz R, Roland PE. Zilles K, et al. J Anat. 1995 Dec;187 ( Pt 3)(Pt 3):515-37. J Anat. 1995. PMID: 8586553 Free PMC article.
• A comparison of the effects of single doses of amoxapine and amitriptyline on autonomic functions in healthy volunteers.
  Bourne M, Szabadi E, Bradshaw CM. Bourne M, et al. Eur J Clin Pharmacol. 1993;44(1):57-62. doi: 10.1007/BF00315281. Eur J Clin Pharmacol. 1993. PMID: 8436156 Clinical Trial.
• Autoradiographic quantification of muscarinic cholinergic synaptic markers in bat, shrew, and rat brain.
  Albin RL, Howland MM, Higgins DS, Frey KA. Albin RL, et al. Neurochem Res. 1994 May;19(5):581-9. doi: 10.1007/BF00971334. Neurochem Res. 1994. PMID: 8065514

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Wiley